Literature DB >> 23809187

Swimming into prominence: the zebrafish as a valuable tool for studying human myopathies and muscular dystrophies.

Elizabeth M Gibbs1, Eric J Horstick, James J Dowling.   

Abstract

A new and exciting phase of muscle disease research has recently been entered. The application of next generation sequencing technology has spurred an unprecedented era of gene discovery for both myopathies and muscular dystrophies. Gene-based therapies for Duchenne muscular dystrophy have entered clinical trial, and several pathway-based therapies are doing so as well for a handful of muscle diseases. While many factors have aided the extraordinary developments in gene discovery and therapy development, the zebrafish model system has emerged as a vital tool in these advancements. In this review, we will highlight how the zebrafish has greatly aided in the identification of new muscle disease genes and in the recognition of novel therapeutic strategies. We will start with a general introduction to the zebrafish as a model, discuss the ways in which muscle disease can be modeled and analyzed in the fish, and conclude with observations from recent studies that highlight the power of the fish as a research tool for muscle disease.
© 2013 FEBS.

Entities:  

Keywords:  birefringence; drug discovery; muscular dystrophy; myopathy; zebrafish

Mesh:

Year:  2013        PMID: 23809187      PMCID: PMC4017590          DOI: 10.1111/febs.12412

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  58 in total

1.  Connexin 39.9 protein is necessary for coordinated activation of slow-twitch muscle and normal behavior in zebrafish.

Authors:  Hiromi Hirata; Hua Wen; Yu Kawakami; Yuriko Naganawa; Kazutoyo Ogino; Kenta Yamada; Louis Saint-Amant; Sean E Low; Wilson W Cui; Weibin Zhou; Shawn M Sprague; Kazuhide Asakawa; Akira Muto; Koichi Kawakami; John Y Kuwada
Journal:  J Biol Chem       Date:  2011-11-10       Impact factor: 5.157

2.  Drug screening in a zebrafish model of Duchenne muscular dystrophy.

Authors:  Genri Kawahara; Jeremy A Karpf; Jennifer A Myers; Matthew S Alexander; Jeffrey R Guyon; Louis M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

3.  In vivo imaging of molecular interactions at damaged sarcolemma.

Authors:  Urmas Roostalu; Uwe Strähle
Journal:  Dev Cell       Date:  2012-03-13       Impact factor: 12.270

4.  The zebrafish dag1 mutant: a novel genetic model for dystroglycanopathies.

Authors:  Vandana Gupta; Genri Kawahara; Stacey R Gundry; Aye T Chen; Wayne I Lencer; Yi Zhou; Leonard I Zon; Louis M Kunkel; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2011-02-04       Impact factor: 6.150

5.  Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy.

Authors:  James J Dowling; Sandrine Arbogast; Junguk Hur; Darcee D Nelson; Anna McEvoy; Trent Waugh; Isabelle Marty; Joel Lunardi; Susan V Brooks; John Y Kuwada; Ana Ferreiro
Journal:  Brain       Date:  2012-03-14       Impact factor: 13.501

6.  Hooked! Modeling human disease in zebrafish.

Authors:  Cristina Santoriello; Leonard I Zon
Journal:  J Clin Invest       Date:  2012-07-02       Impact factor: 14.808

7.  King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene.

Authors:  James J Dowling; Suzanne Lillis; Kimberley Amburgey; Haiyan Zhou; Safa Al-Sarraj; Stefan J A Buk; Elizabeth Wraige; Gabby Chow; Stephen Abbs; Steven Leber; Katherine Lachlan; Diana Baralle; Alexandra Taylor; Caroline Sewry; Francesco Muntoni; Heinz Jungbluth
Journal:  Neuromuscul Disord       Date:  2011-04-22       Impact factor: 4.296

8.  Targeted gene disruption in somatic zebrafish cells using engineered TALENs.

Authors:  Jeffry D Sander; Lindsay Cade; Cyd Khayter; Deepak Reyon; Randall T Peterson; J Keith Joung; Jing-Ruey J Yeh
Journal:  Nat Biotechnol       Date:  2011-08-05       Impact factor: 54.908

9.  Neb: a zebrafish model of nemaline myopathy due to nebulin mutation.

Authors:  William R Telfer; Darcee D Nelson; Trent Waugh; Susan V Brooks; James J Dowling
Journal:  Dis Model Mech       Date:  2011-12-12       Impact factor: 5.758

10.  Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of α-dystroglycan.

Authors:  Tony Roscioli; Erik-Jan Kamsteeg; Karen Buysse; Isabelle Maystadt; Jeroen van Reeuwijk; Christa van den Elzen; Ellen van Beusekom; Moniek Riemersma; Rolph Pfundt; Lisenka E L M Vissers; Margit Schraders; Umut Altunoglu; Michael F Buckley; Han G Brunner; Bernard Grisart; Huiqing Zhou; Joris A Veltman; Christian Gilissen; Grazia M S Mancini; Paul Delrée; Michèl A Willemsen; Danijela Petković Ramadža; David Chitayat; Christopher Bennett; Eamonn Sheridan; Els A J Peeters; Gita M B Tan-Sindhunata; Christine E de Die-Smulders; Koenraad Devriendt; Hülya Kayserili; Osama Abd El-Fattah El-Hashash; Derek L Stemple; Dirk J Lefeber; Yung-Yao Lin; Hans van Bokhoven
Journal:  Nat Genet       Date:  2012-05       Impact factor: 38.330

View more
  28 in total

1.  Zebrafish needle EMG: a new tool for high-throughput drug screens.

Authors:  Sung-Joon Cho; Tai-Seung Nam; Donghak Byun; Seok-Yong Choi; Myeong-Kyu Kim; Sohee Kim
Journal:  J Neurophysiol       Date:  2015-07-15       Impact factor: 2.714

2.  Tmem2 regulates cell-matrix interactions that are essential for muscle fiber attachment.

Authors:  Lucile Ryckebüsch; Lydia Hernandez; Carole Wang; Jenny Phan; Deborah Yelon
Journal:  Development       Date:  2016-07-28       Impact factor: 6.868

3.  POMK mutations disrupt muscle development leading to a spectrum of neuromuscular presentations.

Authors:  Stefania Di Costanzo; Anuradha Balasubramanian; Heather L Pond; Anete Rozkalne; Chiara Pantaleoni; Simona Saredi; Vandana A Gupta; Christine M Sunu; Timothy W Yu; Peter B Kang; Mustafa A Salih; Marina Mora; Emanuela Gussoni; Christopher A Walsh; M Chiara Manzini
Journal:  Hum Mol Genet       Date:  2014-06-11       Impact factor: 6.150

4.  Muscle dysfunction in a zebrafish model of Duchenne muscular dystrophy.

Authors:  Jeffrey J Widrick; Matthew S Alexander; Benjamin Sanchez; Devin E Gibbs; Genri Kawahara; Alan H Beggs; Louis M Kunkel
Journal:  Physiol Genomics       Date:  2016-10-07       Impact factor: 3.107

Review 5.  Animal models for researching approaches to therapy of Duchenne muscular dystrophy.

Authors:  M I Zaynitdinova; A V Lavrov; S A Smirnikhina
Journal:  Transgenic Res       Date:  2021-08-18       Impact factor: 2.788

Review 6.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 7.  Recent advances using zebrafish animal models for muscle disease drug discovery.

Authors:  Lisa Maves
Journal:  Expert Opin Drug Discov       Date:  2014-06-14       Impact factor: 6.098

Review 8.  Gene therapy in monogenic congenital myopathies.

Authors:  Xuan Guan; Melissa A Goddard; David L Mack; Martin K Childers
Journal:  Methods       Date:  2015-10-14       Impact factor: 3.608

9.  Fish is Fish: the use of experimental model species to reveal causes of skeletal diversity in evolution and disease.

Authors:  M P Harris; K Henke; M B Hawkins; P E Witten
Journal:  J Appl Ichthyol       Date:  2014-08-01       Impact factor: 0.892

Review 10.  Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies.

Authors:  Magda Dubińska-Magiera; Marta Migocka-Patrzałek; Damian Lewandowski; Małgorzata Daczewska; Krzysztof Jagla
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.